Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of SUVN-I6107 in Healthy Subjects
NCT06705088Phase 1Completed
- Sponsor
- Suven Life Sciences
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SUVN-I6107 (2 arms), sponsored by Suven Life Sciences. Primary endpoints: Treatment-related adverse events at Day 24, Clinically Significant Changes in Electrocardiogram Values at Day 24 and 5 more. Started Jan 2025; status: completed.
02
Drugs
SUVN-I6107
Beyond the preview
Go deeper on NCT06705088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705088.